Investors & Media

We are driven to develop meaningful therapies for patients while creating value for stockholders.

Investors & Media

Corporate Profile

We are a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing innovative medicines for people with serious diseases of the central nervous system (CNS).

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Presentation July 2022